ADAM10 and neoplasm: Our experiments show that our ‘8C7 antibody–drug conjugates’ specifically kill cells expressing 8C7-reactive ADAM10, and can inhibit the growth of tumours in mice, without significant side effects, suggesting their potential as a novel approach for targeted cancer therapy.